• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Response to crizotinib rechallenge after initial progression and intervening chemotherapy in ALK lung cancer.

作者信息

Browning Eiko Theodora, Weickhardt Andrew James, Camidge D Ross

机构信息

Department of Medicine, Division of Medical Oncology, University of Colorado Denver, Aurora, CO 80045, USA.

出版信息

J Thorac Oncol. 2013 Mar;8(3):e21. doi: 10.1097/JTO.0b013e31827a892c.

DOI:10.1097/JTO.0b013e31827a892c
PMID:23407562
Abstract
摘要

相似文献

1
Response to crizotinib rechallenge after initial progression and intervening chemotherapy in ALK lung cancer.间变性淋巴瘤激酶（ALK）阳性肺癌初始进展及介入化疗后对克唑替尼再激发治疗的反应
J Thorac Oncol. 2013 Mar;8(3):e21. doi: 10.1097/JTO.0b013e31827a892c.
2
Choroidal metastases responsive to crizotinib therapy in a lung adenocarcinoma patient with ALK 2p23 fusion identified by ALK immunohistochemistry.一名肺腺癌患者经ALK免疫组化鉴定存在ALK 2p23融合，其脉络膜转移灶对克唑替尼治疗有反应。
J Thorac Oncol. 2013 Dec;8(12):e109-11. doi: 10.1097/01.JTO.0000437502.82078.9b.
3
Is there a progression-free survival benefit of first-line crizotinib versus standard chemotherapy and second-line crizotinib in ALK-positive advanced lung adenocarcinoma? A retrospective study of Chinese patients.在ALK阳性的晚期肺腺癌患者中，一线克唑替尼相对于标准化疗以及二线克唑替尼在无进展生存期方面是否具有获益？一项针对中国患者的回顾性研究。
Cancer Med. 2016 Jun;5(6):1013-21. doi: 10.1002/cam4.659. Epub 2016 Feb 16.
4
Effectiveness of crizotinib in a patient with ALK IHC-positive/FISH-negative metastatic lung adenocarcinoma.克唑替尼在一名ALK免疫组化阳性/荧光原位杂交阴性转移性肺腺癌患者中的疗效。
Lung Cancer. 2016 Aug;98:118-121. doi: 10.1016/j.lungcan.2016.06.001. Epub 2016 Jun 3.
5
A dramatic response to crizotinib in a non-small-cell lung cancer patient with IHC-positive and FISH-negative ALK.一名免疫组化阳性、荧光原位杂交阴性的间变性淋巴瘤激酶（ALK）非小细胞肺癌患者对克唑替尼产生显著反应。
J Thorac Oncol. 2012 Dec;7(12):e36-e38. doi: 10.1097/JTO.0b013e318274694e.
6
Dramatic response to crizotinib in an ALK-positive adenocarcinoma patient with disseminated intravascular coagulation.一名ALK阳性腺癌合并弥散性血管内凝血患者对克唑替尼产生显著反应。
J Thorac Oncol. 2013 Nov;8(11):e96-8. doi: 10.1097/JTO.0b013e3182a008ed.
7
BIRC6-ALK, a Novel Fusion Gene in ALK Break-Apart FISH-Negative Lung Adenocarcinoma, Responds to Crizotinib.BIRC6-ALK，一种在ALK断裂分离FISH阴性肺腺癌中的新型融合基因，对克唑替尼有反应。
J Thorac Oncol. 2015 Jun;10(6):e37-9. doi: 10.1097/JTO.0000000000000467.
8
Remarkable tumor response to crizotinib in a 14-year-old girl with ALK-positive non-small-cell lung cancer.一名14岁ALK阳性非小细胞肺癌女孩对克唑替尼有显著的肿瘤反应。
J Clin Oncol. 2012 Jun 1;30(16):e147-50. doi: 10.1200/JCO.2011.39.9766. Epub 2012 Apr 16.
9
Response to chemotherapy, reexposure to crizotinib and treatment with a novel ALK inhibitor in a patient with acquired crizotinib resistance.一名获得性克唑替尼耐药患者对化疗的反应、再次暴露于克唑替尼以及使用新型ALK抑制剂进行治疗
Respiration. 2014;88(3):262-4. doi: 10.1159/000364949. Epub 2014 Aug 7.
10
Crizotinib Response in a Late Relapse of ALK-positive Lung Adenocarcinoma.克唑替尼对ALK阳性肺腺癌晚期复发的疗效
Appl Immunohistochem Mol Morphol. 2016 Oct;24(9):e86-e88. doi: 10.1097/PAI.0000000000000328.

引用本文的文献

1
CCN1 is a therapeutic target upregulated in EML4-ALK mutant lung adenocarcinoma reversibly resistant to alectinib.CCN1是一种在对阿来替尼可逆耐药的EML4-ALK突变型肺腺癌中上调的治疗靶点。
Cell Death Dis. 2025 Apr 15;16(1):303. doi: 10.1038/s41419-025-07601-4.
2
Heuristic value-based framework for lung cancer decision-making.基于启发式价值的肺癌决策框架。
Oncotarget. 2018 Jul 6;9(52):29877-29891. doi: 10.18632/oncotarget.25643.
3
A Convergence-Based Framework for Cancer Drug Resistance.基于融合的癌症药物耐药性研究框架
Cancer Cell. 2018 May 14;33(5):801-815. doi: 10.1016/j.ccell.2018.03.025.
4
Overall survival with crizotinib and next-generation ALK inhibitors in ALK-positive non-small-cell lung cancer (IFCT-1302 CLINALK): a French nationwide cohort retrospective study.克唑替尼与新一代ALK抑制剂用于ALK阳性非小细胞肺癌的总生存期（IFCT-1302 CLINALK）：一项法国全国队列回顾性研究
Oncotarget. 2017 Mar 28;8(13):21903-21917. doi: 10.18632/oncotarget.15746.
5
Resisting Resistance: Targeted Therapies in Lung Cancer.对抗耐药性：肺癌的靶向治疗
Trends Cancer. 2016 Jul;2(7):350-364. doi: 10.1016/j.trecan.2016.05.010.
6
A patient previously treated with ALK inhibitors for central nervous system lesions from ALK rearranged lung cancer: a case report.
Onco Targets Ther. 2016 Oct 12;9:6059-6063. doi: 10.2147/OTT.S112833. eCollection 2016.
7
The pharmacogenomics of drug resistance to protein kinase inhibitors.蛋白激酶抑制剂耐药性的药物基因组学
Drug Resist Updat. 2016 Sep;28:28-42. doi: 10.1016/j.drup.2016.06.008. Epub 2016 Jul 5.
8
Oncogene Overdose: Too Much of a Bad Thing for Oncogene-Addicted Cancer Cells.癌基因过量：对癌基因成瘾的癌细胞而言，过量是件坏事。
Biomark Cancer. 2015 Dec 15;7(Suppl 2):25-32. doi: 10.4137/BIC.S29326. eCollection 2015.
9
Kinase overexpressing cancers responsive to drug withdrawal.对药物撤药有反应的激酶过表达癌症。
Aging (Albany NY). 2015 Oct;7(10):752-3. doi: 10.18632/aging.100830.
10
Practical tips and tricks with recently approved molecular targeted agents in non-small-cell lung cancer.非小细胞肺癌中近期获批的分子靶向药物的实用技巧和窍门
EJC Suppl. 2013 Sep;11(2):307-9. doi: 10.1016/j.ejcsup.2013.07.058.